Oct 18, 2024
In the ever-evolving world of liver disease, the shift from Nonalcoholic Steatohepatitis (NASH) to Metabolic Associated Steatotic Hepatitis (MASH) marks a revolutionary leap in our understanding and approach to treatment. This transition isn't merely a rebranding; it signifies a profound recognition of the intricat...
Read More...
Mar 17, 2017
Fatty liver disease is the common form of Non-alcoholic fatty liver disease (NAFLD), whereas very extreme form of NAFLD is termed as Non-alcoholic Steatohepatitis (NASH). NASH is characterized by deposition of fat with 5%-10% of liver weight in liver of people who drink very little or no drinking leading to inflamma...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
Newsletter/Whitepaper